158 related articles for article (PubMed ID: 37258452)
1. Role of Advanced MR Imaging in Diagnosis of Neurological Malignancies: Current Status and Future Perspective.
Eraky AM; Beck RT; Treffy RW; Aaronson DM; Hedayat H
J Integr Neurosci; 2023 May; 22(3):73. PubMed ID: 37258452
[TBL] [Abstract][Full Text] [Related]
2. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
[TBL] [Abstract][Full Text] [Related]
3. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
4. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma.
Manning P; Daghighi S; Rajaratnam MK; Parthiban S; Bahrami N; Dale AM; Bolar D; Piccioni DE; McDonald CR; Farid N
J Neurooncol; 2020 May; 147(3):681-690. PubMed ID: 32239431
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
7. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
8. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
[TBL] [Abstract][Full Text] [Related]
11. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
[TBL] [Abstract][Full Text] [Related]
12. MR diffusion and dynamic-contrast enhanced imaging to distinguish meningioma, paraganglioma, and schwannoma in the cerebellopontine angle and jugular foramen.
Ota Y; Liao E; Capizzano AA; Yokota H; Baba A; Kurokawa R; Kurokawa M; Moritani T; Yoshii K; Srinivasan A
J Neuroimaging; 2022 May; 32(3):502-510. PubMed ID: 34936708
[TBL] [Abstract][Full Text] [Related]
13. Radiological Biomarkers for Brain Metastases Prognosis: Quantitative Magnetic Resonance Imaging (MRI) Modalities As Non-invasive Biomarkers for the Effect of Radiotherapy.
Eraky AM
Cureus; 2023 Apr; 15(4):e38353. PubMed ID: 37266043
[TBL] [Abstract][Full Text] [Related]
14. Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.
Hangel G; Schmitz-Abecassis B; Sollmann N; Pinto J; Arzanforoosh F; Barkhof F; Booth T; Calvo-Imirizaldu M; Cassia G; Chmelik M; Clement P; Ercan E; Fernández-Seara MA; Furtner J; Fuster-Garcia E; Grech-Sollars M; Guven NT; Hatay GH; Karami G; Keil VC; Kim M; Koekkoek JAF; Kukran S; Mancini L; Nechifor RE; Özcan A; Ozturk-Isik E; Piskin S; Schmainda KM; Svensson SF; Tseng CH; Unnikrishnan S; Vos F; Warnert E; Zhao MY; Jancalek R; Nunes T; Hirschler L; Smits M; Petr J; Emblem KE
J Magn Reson Imaging; 2023 Jun; 57(6):1676-1695. PubMed ID: 36912262
[TBL] [Abstract][Full Text] [Related]
15. Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
Xu Q; Liu Q; Ge H; Ge X; Wu J; Qu J; Xu K
Medicine (Baltimore); 2017 Dec; 96(50):e9332. PubMed ID: 29390403
[TBL] [Abstract][Full Text] [Related]
16. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
[TBL] [Abstract][Full Text] [Related]
17. Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme.
Jovanovic M; Radenkovic S; Stosic-Opincal T; Lavrnic S; Gavrilovic S; Lazovic-Popovic B; Soldatovic I; Maksimovic R
J BUON; 2017; 22(4):1061-1067. PubMed ID: 28952228
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
[TBL] [Abstract][Full Text] [Related]
19. Advanced magnetic resonance imaging in glioblastoma: a review.
Shukla G; Alexander GS; Bakas S; Nikam R; Talekar K; Palmer JD; Shi W
Chin Clin Oncol; 2017 Aug; 6(4):40. PubMed ID: 28841802
[TBL] [Abstract][Full Text] [Related]
20. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
